Serum levels of chemokines in patients with thalassemia and healthy controls
| . | Control (N = 73) . | Thalassemia carriers . | ||||
|---|---|---|---|---|---|---|
| All (N = 83) . | α-Silent carriers (n = 32) . | α-Thalassemia minor (n = 35) . | β-Thalassemia minor (n = 9) . | β-Thalassemia minor combined with α-silent or α-thalassemia minor (n = 7) . | ||
| CCL2 (pg/mL) | 51.0 (8.7-642.3) | 38.5 (6.6-200.3)∗∗ | 40.1 (6.6-200.3) | 34.6 (12.3-100.7)∗∗ | 30.5 (11.0-162.1) | 50.5 (37.1-64.0) |
| CCL11 (pg/mL) | 32.5 (0.0-553.6) | 26.0 (6.3-126.0)∗∗ | 30.1 (14.8-100.4) | 22.7 (11.7-126.0)∗∗∗ | 21.2 (16.1-87.8) | 24.2 (6.3-77.3) |
| CCL17 (pg/mL) | 13.6 (3.9-64.6) | 9.5 (2.2-128.9)∗ | 10.9 (2.4-128.9) | 8.8 (2.2-41.3)∗∗∗ | 6.4 (3.9-48.4) | 14.1 (2.2-70.1) |
| CXCL11 (pg/mL) | 36.0 (16.9-366.4) | 41.6 (18.4-156.7)∗ | 40.7 (18.4-156.7) | 41.6 (20.9-83.3) | 52.9 (28.3-107.1)∗ | 39.4 (24.7-101.1) |
| . | Control (N = 73) . | Thalassemia carriers . | ||||
|---|---|---|---|---|---|---|
| All (N = 83) . | α-Silent carriers (n = 32) . | α-Thalassemia minor (n = 35) . | β-Thalassemia minor (n = 9) . | β-Thalassemia minor combined with α-silent or α-thalassemia minor (n = 7) . | ||
| CCL2 (pg/mL) | 51.0 (8.7-642.3) | 38.5 (6.6-200.3)∗∗ | 40.1 (6.6-200.3) | 34.6 (12.3-100.7)∗∗ | 30.5 (11.0-162.1) | 50.5 (37.1-64.0) |
| CCL11 (pg/mL) | 32.5 (0.0-553.6) | 26.0 (6.3-126.0)∗∗ | 30.1 (14.8-100.4) | 22.7 (11.7-126.0)∗∗∗ | 21.2 (16.1-87.8) | 24.2 (6.3-77.3) |
| CCL17 (pg/mL) | 13.6 (3.9-64.6) | 9.5 (2.2-128.9)∗ | 10.9 (2.4-128.9) | 8.8 (2.2-41.3)∗∗∗ | 6.4 (3.9-48.4) | 14.1 (2.2-70.1) |
| CXCL11 (pg/mL) | 36.0 (16.9-366.4) | 41.6 (18.4-156.7)∗ | 40.7 (18.4-156.7) | 41.6 (20.9-83.3) | 52.9 (28.3-107.1)∗ | 39.4 (24.7-101.1) |
Levels of cytokines (pg/mL) are expressed as median (Q1-Q3). Statistical significance was determined for patient groups in comparison with healthy controls using Mann-Whitney U test. ∗P < .05; ∗∗P < .01; ∗∗∗P < .001.
Q1, quartile 1.